Trial Profile
A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimeperide Alone or in Combination With Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Feb 2014 Results published in the Drugs and Aging.
- 14 Mar 2008 New trial record.